Optical Clearing of the Skin in Conjunction With Laser Treatments
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00580736|
Recruitment Status : Completed
First Posted : December 27, 2007
Last Update Posted : October 20, 2022
|Condition or disease||Intervention/treatment||Phase|
|Port Wine Stain Nevus of Ota Tattoos Scars Acne Hypertrichosis Sebaceous Gland Diseases||Device: Optical Clearing||Phase 1|
The researchers expect that application of the optical clearing agent for treatment of benign vascular lesions, tattoos, nevus of Ota, hypertrichosis, scars, acne and sebaceous hyperplasia will result in
- decreased reflectance of the predominant color from the surface of skin (decreased red light scattering in case of benign vascular lesions, etc) as compared to the control group.
- greater Optical Coherence Tomography a non-invasive light based imaging method imaging depth as compared to the control group.
- greater improvement in the treatment outcome (decrease in the erythema index following laser treatment of vascular lesions as compared to the laser alone group; improved lightening of the tattoo or nevus of Ota as compared to the laser treatment alone group; significant decrease in hair re-growth as compared to laser treatment alone in patients seeking hair removal; greater improvement of scars, acne and sebaceous hyperplasia).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||35 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Optical Clearing of the Skin in Conjunction With Laser Treatments|
|Study Start Date :||March 2004|
|Actual Primary Completion Date :||July 2008|
|Actual Study Completion Date :||July 2008|
Experimental: Optical Clearing
Device: Optical Clearing
- Outcome measure is to evaluate the optical clearing effects of the combination mixture of pre-polymers of polypropylene glycol and polyethylene glycol. [ Time Frame: 8 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00580736
|United States, California|
|Beckman Laser Institute Medical and Surgical Clinic|
|Irvine, California, United States, 92612|
|Principal Investigator:||Kristen M Kelly, M.D||Beckman Laser Institute|